A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of HRS-2129 and the Food Effect on Pharmacokinetics Following Single Dose Administration in Healthy Subjects

Shandong Suncadia Medicine Co., Ltd.1 个研究点分布在 1 个国家目标入组 44 人开始时间: 2024年10月17日最近更新: 2025年3月5日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 44
试验地点: 1
主要终点: The incidence and severity of adverse events

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics in healthy subjects, and to evaluate the food effect on pharmacokinetics of HRS-2129.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Age: 18 to 55 years old (inclusive);
•Body weight: ≥ 50 kg for male and ≥ 45 kg for female, body mass index: 19.0 ~ 28.0 kg/m2 (inclusive);
•Subject has no plan to give a birth, donate sperm or eggs from signing the informed consent form to 6 months after last dose;
•Female subjects: non-pregnant or non-lactating;
•The skin to receive pain stimuli has no wound or derma disease.
•Subject who is willing to accept cold pain test.
•Subject who voluntarily signs the informed consent.

排除标准

•Subject who suffers from clinical acute and chronic diseases of circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities;
•Subject with the following abnormalities: aspartate aminotransferase, alanine aminotransferase, total bilirubin, or serum creatine value exceeds the upper limit of the normal range, QTcF > 450 ms, hyperpotassemia or hypopotassemia;
•Subject with a history of torsade de pointes, symptomatic ventricular arrhythmia, or personal or family history of short QT syndrome or long QT syndrome;
•Subject with a history of allergies to the IMP or its excipients, or subject with allergic constitution;
•Subject who underwent major surgery within 6 months prior to screening, or received surgery that may significantly affect the pharmacokinetics or safety evaluation of the IMP, or who plans to undergo surgery during the study period;
•Subject with a medication history that inhibits or induces liver metabolism of drug has been used within 1 month before administration;
•Subject with vaccinated within 1 month prior to screening or plan to be vaccinated during the study;
•Subject who used any drugs or health products (including Chinese herbal medicines) within 7 half-lives or 14 days (whichever is longer) before administration, or who plans to receive other drug treatments during the study;
•Subject who has participated in clinical trials and received experimental drugs within 3 months before screening, or plans to participate in other clinical trials during this study;
•Donate blood/blood loss ≥ 400 mL within 3 months before screening;
•Subject who smoked more than 5 cigarettes per day on average within 3 months before screening;
•Drink more than 14 units of alcohol per week on average;
•Drink excessive tea, coffee or caffeinated beverages within 3 months before screening;
•Consume special food (such as grapefruit, grapefruit juice or food/drink containing grapefruit juice, chocolate, tobacco, alcohol, caffeine and other food or drink) within 48 hours before administration;
•Subject who has special requirements for diet and cannot follow a unified diet;
•Subject with clinical significant abnormalities in medical examination;
•Subject with positive tests for hepatitis B surface antigen, hepatitis C virus antibody, syphilis or human immunodeficiency virus antibody;
•Subject with a history of drug abuse or with a positive result for drug abuse test;
•Alcohol test result is positive;
•Subject who has difficulty in swallowing, or venous blood collection, or who cannot tolerate venipuncture, or who has a history of fainting of needle or blood;
•Subject may not be able to complete the study due to other reasons or the investigators considers that he is not suitable for inclusion.

研究组 & 干预措施

Treatment at dose level 1

Experimental

干预措施: HRS-2129 (Drug)